Top Back to top

2nd European CAR T Cell Meeting

Date:
-
City:
Sitges
Country:
Spain

Welcome

 

Dear Colleagues and Friends,

Following the great success of the first edition held in Paris in February 2019, the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA) are teaming up again to bring to preclinical and clinical investigators from Europe and beyond, the 2nd edition of this European CAR-T Cell Meeting. The two professional associations are dedicated to raising awareness of the potential value of this new class of therapeutics, as well as to foster European preclinical and clinical initiatives

The recent approval of the first CAR T cell treatments in Europe presents a great opportunity to fight hematological malignancies, but also poses serious challenges given the peculiar nature of the treatment. Patients, physicians, nurses, hospitals and whole health systems need to learn how to select the right treatments, handle specific toxicities, organize treatment units and cope with the increasing costs connected with CAR T therapy.

This meeting will build on the knowledge and experience shared at the first joint meeting and will see the return of a number of key opinion leaders to give updates on the rapid developments in this exciting therapy. The program will include a comprehensive outlook on the current research efforts in Europe, the USA and China to increase access to CAR T cell therapies, evaluate new targets, improve efficacy and safety profiles, with input from basic researchers as well as representatives from the industry.

The target audience is hematologists, oncologists, physicians, nurses, data managers, supply chain managers and patient organization representatives and advocates.

We look forward to seeing you in Sitges (Barcelona), Spain this coming January for this noteworthy and influential Meeting dedicated to CAR T Cell therapies.

Yours sincerely,

Prof Christian Chabannon
Chair, EBMT Cellular Therapy & Immunobiology Working Party
and EBMT Scientific Council Vice-Chair

Prof Hermann Einsele
Chair, EHA-SWG on Immune Therapies for Hematologic Disorders

Registration

Online registration is now open. These fees include:

  • Access to the scientific and educational sessions of the meeting
  • Meeting materials
  • Coffee/tea breaks and lunches on all 3 meeting days

Fees

Early registration fee deadline: 11th November 2019
The registration closes on the 26th January 2020

Please keep in mind that data managers, nurses and students (medical residents are not considered to be students) will need to provide proof of their status, in the form of an ID or a letter from their institution during the registration. 
Patient advocates should upload a screenshot of their membership.

The above mentioned registration fee benefits do not apply to the Saturday pass, which only grants access to the meeting, coffee breaks and lunch on Saturday, 1st February .

* Member of EHA and/or EBMT. Only members who have paid their membership fee are eligible to receive the discounted registration fee. Check your EBMT membership by contacting membership@ebmt.org, or your EHA membership status by contacting membership@ehaweb.org.

If you are not part of EBMT yet please consider becoming a Member. For more information visit this page.

 

Group registration

You can register up to 20 attendees per transaction

Registration Cancellation

Refund of registration fees will be as follows:

  • In case of cancellation, up until one month prior to the beginning of the meeting, your registration fee will be reimbursed in full (less all administrative costs)
  • If the cancellation is notified between 30 and 15 days prior to the beginning of the meeting, 50% of the registration fee will be reimbursed (less all administrative costs)
  • Cancellations notified between 15 and 1 day, registration fee will not be refunded
  • Name changes: Permitted up to 15 days. The current available fee will be applied

 

Programme

ABOUT THE PROGRAMME

The meeting begins on Thursday 30th January at 12:00h and ends on Saturday 1st February at 16:45h. 
Please visit this page regularly for the most up to date programme. 

This meeting will cover the following topics:
 

  • The current state of CAR T cells in Europe
  • Improvement of the efficacy and safety profile
  • Pediatrics and CAR T
  • Latest clinical & pre-clinical data
  • CAR effector cells
  • Optimization of CAR T treatment
  • CAR T regulatory aspects
  • Implementation of CAR T cells
  • Nurses sessions
  • Data Management sessions

With key-note lectures by: 

  • Professor Martin Pule |  University College London, London, United Kingdom
  • Professor Crystal Mackall  | Stanford University, Stanford, USA
  • Professor Jianxiang Wang  |  Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China
  • Professor Carl June  |  University of Pennsylvania, Philadelphia, USA
  • Professor Michel Sadelain   |  Memorial Sloan Kettering Cancer Center, New York, USA
  • Professor Stanley Riddell   |  Fred Hutchinson Cancer Research Center, Seattle, USA

Full programme will be announced shortly. 

Abstracts


Abstract submission has officially opened    Click here to submit 

Abstract submission is an important part of the 2nd European CAR T Cell Meeting. As a participant, you will have the opportunity to submit an abstract for this meeting, and (if accepted) have the possibility to discuss it with the international faculty and your peers.

A selection of abstracts will be eligible for acceptance during the meeting, the presentation format will be in the form of oral presentations or poster presentations. Presenting authors will receive a separate invitation. 

As a consequence of the high appreciation expressed by delegates for the flash talk session at the 1st edition of the EU CAR-T Cell meeting, the Scientific Program Committee has decided to include two sessions during the 2nd edition. A particular attention will be paid to presentations of emerging projects and initiatives in Europe. Abstract submission will close on the 15th November 2019 (23:59 UTC).

as

Topics

You can submit an abstract on one of the following topics:

CAR-based therapeutic approaches for
  • Acute lymphoblastic leukemia - Biology & Translational Research
  • Acute lymphoblastic leukemia - Clinical
  • Acute myeloid leukemia - Biology & Translational Research
  • Acute myeloid leukemia - Clinical
  • Chronic lymphocytic leukemia and related disorders - Biology & Translational Research
  • Chronic lymphocytic leukemia and related disorders – Clinical
  • Myeloma and other monoclonal gammopathies - Biology & Translational Research
  • Myeloma and other monoclonal gammopathies - Clinical
  • Hodgkin lymphoma - Biology & Translational Research
  • Hodgkin lymphoma - Clinical
  • Non-Hodgkin lymphoma Biology & Translational Research
  • Non-Hodgkin lymphoma - Clinical
  • Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research
  • Gene therapy, cellular immunotherapy and vaccination - Clinical
  • Clinical implementation of immune effector cell based therapies, including combinatorial approaches with other immune therapies
  • Solid tumor and autoimmune disorders
  • Medico-economics, regulatory and patients acceptance aspects of CAR-T Cell therapies

Submission

The abstracts will be reviewed and allocated by the Organising Committee. Submitting authors will be informed about the allocation before the 1st December 2019.

Please note that the submission of an abstract constitutes a formal commitment by the author to attend the meeting (if the abstract is accepted) and if required present the abstract as an oral presentation or poster presentation in the session and the time assigned by the Scientific Program Committee. Presenting authors of accepted abstracts will be allowed to register for the early registration fee, for which the details will be shared in the acceptance letter. All other authors wishing to attend the meeting should register before the 10th November to make use of the early registration fee. To register, click here.

Should you have any questions concerning the abstract submissions, please contact scientificmeetings@ehaweb.org.

Venue

The meeting will take place at Melia Sitges Hotel:


Carrer de Joan Salvat Papasseit 38
08870 Sitges
Barcelona, Spain

 

Accommodation 

Participants will be responsible for covering their costs of travel & accommodation aswell as a recommended travel insurance.

The Organisation cannot accept liability for personal accidents or loss of or damage to private property of participants. Participants are advised to take out their own personal travel and health insurance for their trip.

Some additional information will be given upon registration.

Hotels

EBAH-CME Accreditation

Continuing Medical Education (CME) is widely accepted to encourage individual practitioners to maintain and develop professional knowledge and skills keeping up-to-date with latest developments within the field. The meeting will be accredited by the EBAH system.

Participants of this meeting are eligible to receive one Continuing Medical Education (CME) credit point for every hour of accredited activity from the EBAH system.

Supreme level partner 

 

Kite

 

Novartis

Premium level partner

Celgene

Meeting partner

Janssen

Meeting planner

miltenyi

Meeting contributor

bbb

 

Octapharma

Sponsorship

There are various opportunities to support this meeting. For more information please send an email to fundraising@ebmt.org to indicate your interest.

 

 

 

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to data.protection@ebmt.org